Nanobiotix S.A (NANO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Nanobiotix S.A (NANO) has a cash flow conversion efficiency ratio of 0.253x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-17.41 Million ≈ $-20.36 Million USD) by net assets (€-68.95 Million ≈ $-80.61 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Nanobiotix S.A market cap and net worth for the company's overall valuation and market capitalisation.
Nanobiotix S.A - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Nanobiotix S.A's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Nanobiotix S.A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nanobiotix S.A ranked by their cash flow conversion efficiency. See how well can Nanobiotix S.A service its debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sylvamo Corp
NYSE:SLVM
|
-0.010x |
|
Hubei Jianghan New Materials Co. Ltd. A
SHG:603281
|
N/A |
|
Anhui Guangxin Agrochemical Co Ltd
SHG:603599
|
0.011x |
|
Xinjiang Machinery Research Inst
SHE:300159
|
0.010x |
|
Wuxi Shangji Automation Co Ltd
SHG:603185
|
0.051x |
|
Companhiade Eletricidade do Estado da Bahia - COELBA
SA:CEEB3
|
-0.001x |
|
Liberty Latin America Ltd Class C
NASDAQ:LILAK
|
0.261x |
|
Peugeot Invest SA
PA:PEUG
|
-0.013x |
Annual Cash Flow Conversion Efficiency for Nanobiotix S.A (2011–2024)
The table below shows the annual cash flow conversion efficiency of Nanobiotix S.A from 2011 to 2024. View Nanobiotix S.A (NANO) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-65.70 Million ≈ $-76.81 Million |
€-19.55 Million ≈ $-22.86 Million |
0.298x | -95.60% |
| 2023-12-31 | €-1.84 Million ≈ $-2.15 Million |
€-12.48 Million ≈ $-14.59 Million |
6.769x | +393.43% |
| 2022-12-31 | €-27.05 Million ≈ $-31.62 Million |
€-37.10 Million ≈ $-43.38 Million |
1.372x | +218.11% |
| 2021-12-31 | €26.69 Million ≈ $31.21 Million |
€-31.00 Million ≈ $-36.25 Million |
-1.162x | -189.43% |
| 2020-12-31 | €70.36 Million ≈ $82.26 Million |
€-28.24 Million ≈ $-33.01 Million |
-0.401x | -101.97% |
| 2019-12-31 | €-2.04 Million ≈ $-2.38 Million |
€-41.52 Million ≈ $-48.54 Million |
20.362x | +1216.11% |
| 2018-12-31 | €14.24 Million ≈ $16.65 Million |
€-25.98 Million ≈ $-30.38 Million |
-1.824x | -282.51% |
| 2017-12-31 | €43.92 Million ≈ $51.35 Million |
€-20.95 Million ≈ $-24.49 Million |
-0.477x | +54.61% |
| 2016-12-31 | €17.40 Million ≈ $20.34 Million |
€-18.28 Million ≈ $-21.38 Million |
-1.051x | +2.47% |
| 2015-12-31 | €15.61 Million ≈ $18.25 Million |
€-16.82 Million ≈ $-19.66 Million |
-1.077x | -281.37% |
| 2014-12-31 | €30.32 Million ≈ $35.44 Million |
€-8.56 Million ≈ $-10.01 Million |
-0.283x | +86.84% |
| 2013-12-31 | €3.18 Million ≈ $3.72 Million |
€-6.83 Million ≈ $-7.99 Million |
-2.147x | -506.57% |
| 2012-12-31 | €10.70 Million ≈ $12.51 Million |
€-3.79 Million ≈ $-4.43 Million |
-0.354x | +93.28% |
| 2011-12-31 | €925.53K ≈ $1.08 Million |
€-4.87 Million ≈ $-5.70 Million |
-5.265x | -- |
About Nanobiotix S.A
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esop… Read more